Skip to content
Family History of breast cancer
avatar
An_248867 posted:
My mother had breast cancer at age 50 had a mastectomy with no other treatment course. She got recurring breast cancer at age 90 and recently passed away from it.

Sister # 1 got breast cancer at age 46 had a mastectomy and chemo. At age 70 got recurring breast cancer opposite side and is currently under chemo.

Sister # 2 got breast cancer at age 48 had a lumpectomy followed by radiation and tamoxifen for 5 years developed ovarian cancer which was contained no treatment necessary. 4 years later developed recurring breast cancer in the left breast and has now chosen to have a double mastectomy this month.

Sister # 3 got breast cancer at age 60 had a lumpectomy followed by radiation and tamoxifen for 5 years.

Sister # 4 This one is me I got the breast cancer at age 65 had a lumpectomy followed by radiation and tamoxifen.

5 women in the same family with breast cancer. We have all been tested and not a one of us has a positive BRACA 1 or 2 gene. We have been fighting this disease for over 40 years and we are fed up.

CAN YOU PLEASE TELL ME IF THERE IS ANY OTHER FORM OF TESTING WE CAN HAVE TO DETERMINE THE INORDINATE AMOUNT OF BREAST CANCER IN OUR FAMILY.
Reply
 
avatar
rachael67 responded:
What a nightmare for you and everyone in your family! I am so very sorry.

I am assuming you have sought the help of a a genetic counselor, right? If not, please do so!! That is the individual who might offer the best information/leads to you.

I just recently saw the enclosed article in the Science News Magazine (Oct, 2012). I will copy it here. (If it goes beyond this one post, I will continue on another.) The study is only in the formative stages, but might offer some insight for you.

Blessings.
Rachael

Breast cancer gets genetic profileData may help improve treatmentBy Tina Hesman Saey
Web edition: September 25, 2012
Print edition: October 20, 2012; Vol.182 #8 (p.

One of the most complete portraits of breast cancer yet painted may inspire some new treatment options.
Doctors and researchers have long classified breast cancer into four different types. But those sketches contain information about only one aspect of tumors and do not show all facets of the cancer's molecular personality, including mutations, protein production and levels of genetic activity. Now, an international consortium of researchers known as the Cancer Genome Atlas Network has combined many different types of data to fill in the picture, including the mutations that probably sparked tumor formation in the first place. The molecular portraits were published online September 23 in Nature.
Breast cancers are usually categorized by which genes are highly active. Tumors with an overactive estrogen receptor gene are known as ER-positive and fall into two groups: the easier-to-treat luminal A group and a more aggressive luminal B group. Another category is based on the activity of the HER2 gene.
The fourth category, basal-like tumors, sometimes called triple-negative tumors, is different from the rest. This type of breast cancer is aggressive, tends to strike younger women, African-Americans and women with a family history of the disease. It is also associated with mutations in the BRCA1gene, which are associated with a greatly increased risk of breast cancer.
Knowing a tumor's category has helped doctors advise patients about treatments, but hasn't offered information about the underlying cause of the disease, says Matthew Ellis, an oncologist and molecular biologist at Washington University School of Medicine in St. Louis. Ellis was one of hundreds of coauthors of the paper.
Information from the new study shows that basal-like breast cancer strongly resembles a type of ovarian tumor called serous ovarian cancer.
"This is what we hoped to find," says Philip Bernard, a genomics researcher at Huntsman Cancer Institute at the University of Utah, who was not involved in the study. "It was expected"026but it still needed to be confirmed."
So women with these basal-like tumors may benefit from chemotherapy regimens like those given to patients with ovarian cancer, Ellis says. He expects fierce debate and probably some clinical trials to test that conclusion.
In the three other types of breast cancer, a series of biochemical reactions known as the PI3 kinase pathway is overstimulated because of mutations in genes involved at different steps of the process. Some drugs that target specific mutations in genes involved in the PI3 kinase pathway are already being tested against other types of cancer and might be appropriate for some women with breast cancer, the study results suggest.
Ellis professes to worrying that "chaos will ensue unless we get ourselves organized" and decide how best to test drugs developed for other types of cancer in patients with breast cancer. Insurance companies generally will not pay for such off-label use of cancer drugs.
The new study also uncovered new mutations not previously associated with breast cancer. Drugs might be developed to combat some of those newly discovered molecular changes, Ellis says.
Just when the caterpillar thought her world was over, she became a butterfly! Don't give up five minutes before the miracle!!


Helpful Tips

How to more easily read discussions
Exchanges provide a more dynamic way to keep up with ongoing discussions. But If you're finding how discussions and responses are ... More
Was this Helpful?
27 of 46 found this helpful

Related News

There was an error with this newsfeed

Related Drug Reviews

  • Drug Name User Reviews

Report Problems With Your Medications to the FDA

FDAYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

For more information, visit the Duke Health Breast Cancer Center